These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 10073331)
1. Case report: rhabdomyolysis induced by mibefradil in a patient treated with cyclosporine and simvastatin. Wombolt DG; Jackson A; Punn R; Smith S; McCune TR; Williams PB J Clin Pharmacol; 1999 Mar; 39(3):310-2. PubMed ID: 10073331 [No Abstract] [Full Text] [Related]
2. Rhabdomyolysis due to interaction of simvastatin with mibefradil. Schmassmann-Suhijar D; Bullingham R; Gasser R; Schmutz J; Haefeli WE Lancet; 1998 Jun; 351(9120):1929-30. PubMed ID: 9654265 [No Abstract] [Full Text] [Related]
3. [Induction of bradycardia by mibefradil in antihypertensive combination therapy]. Wagner J; Ritz E Dtsch Med Wochenschr; 1998 Apr; 123(17):547. PubMed ID: 9601479 [No Abstract] [Full Text] [Related]
5. A comparison of the safety and efficacy of mibefradil and nifedipine SR in patients with renal disease and hypertension. Woittiez AJ; Huysmans FT; Bailey R; Robson RA; Mion Júnior D; Villa G; Kobrin I Clin Nephrol; 1998 Mar; 49(3):160-6. PubMed ID: 9543597 [TBL] [Abstract][Full Text] [Related]
6. Simvastatin-induced rhabdomyolysis following cyclosporine treatment for uveitis. Lasocki A; Vote B; Fassett R; Zamir E Ocul Immunol Inflamm; 2007; 15(4):345-6. PubMed ID: 17763133 [TBL] [Abstract][Full Text] [Related]
7. Simvastatin-induced rhabdomyolysis in a CsA-treated renal transplant recipient. Gumprecht J; Zychma M; Grzeszczak W; Kuźniewicz R; Burak W; Zywiec J; Karasek D; Otulski I; Mosur M Med Sci Monit; 2003 Sep; 9(9):CS89-91. PubMed ID: 12960932 [TBL] [Abstract][Full Text] [Related]
8. Mibefradil withdrawn from the market. Billups SJ; Carter BL Ann Pharmacother; 1998; 32(7-8):841. PubMed ID: 9681103 [No Abstract] [Full Text] [Related]
9. Serious interaction between mibefradil and tacrolimus. Krähenbühl S; Menafoglio A; Giostra E; Gallino A Transplantation; 1998 Oct; 66(8):1113-5. PubMed ID: 9808502 [TBL] [Abstract][Full Text] [Related]
10. [Current therapy of coronary heart disease. Conservative measures]. Stephan S Internist (Berl); 1998 Sep; 39(9):1001-2. PubMed ID: 9788131 [No Abstract] [Full Text] [Related]
11. Good news for experimental concept but bad news for clinically effective therapy. Reimer KA; Califf RM Circulation; 1999 Jan; 99(2):198-200. PubMed ID: 9892582 [No Abstract] [Full Text] [Related]
12. Profound symptomatic bradycardia associated with combined mibefradil and beta-blocker therapy. Rogers R; Prpic R Med J Aust; 1998 Oct; 169(8):425-7. PubMed ID: 9830391 [TBL] [Abstract][Full Text] [Related]
13. The withdrawal of mibefradil (Posicor). Griffin JP Adverse Drug React Toxicol Rev; 1998; 17(2-3):59-60. PubMed ID: 9838964 [No Abstract] [Full Text] [Related]
14. [Interaction of cyclosporin with CSE inhibitors]. Martini B Med Monatsschr Pharm; 2006 Oct; 29(10):379. PubMed ID: 17058898 [No Abstract] [Full Text] [Related]
15. [Progress in new cardiovascular treatment. Background discussion and interview in the Basel Roche Research Center]. Keil U Fortschr Med; 1996 Feb; 114(4):39-40. PubMed ID: 8852686 [No Abstract] [Full Text] [Related]
16. The efficacy and safety of mibefradil in subgroups of patients with chronic stable angina pectoris. Charlon V; Kobrin I Int J Clin Pract; 1998 Jun; 52(4):257-64. PubMed ID: 9744152 [TBL] [Abstract][Full Text] [Related]
17. Rhabdomyolysis after concomitant use of cyclosporine and simvastatin in a patient transplanted for multiple myeloma. Tong J; Laport G; Lowsky R Bone Marrow Transplant; 2005 Oct; 36(8):739-40. PubMed ID: 16086041 [No Abstract] [Full Text] [Related]